Drug Approval | June 25, 2024
Lupin receives EIR from US FDA for its Somerset manufacturing facility
The facility was inspected from May 7 to May 17, 2024
The facility was inspected from May 7 to May 17, 2024
FDA has concluded that this inspection is 'closed'
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.
The inspection classification was determined by the agency as Voluntary Action Indicated
The inspection closed with zero observations and a classification of No Action Indicated
The inspection closed with zero observations
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
Subscribe To Our Newsletter & Stay Updated
